rs199759556
Variant summary
Our verdict is Benign. The variant received -6 ACMG points: 0P and 6B. BP7BS1BP4
This summary comes from the ClinGen Evidence Repository: The c.648C>T (p.Pro216=) variant is a synonymous (silent) variant that is not predicted by SpliceAI to impact splicing (BP4); in addition, an evolutionary conservation algorithm predicts the site as being non-conserved (PhyloP score = -2.75191 in GRCh38), and the variant allele is the reference nucleotide in one primate and/or three mammal species (BP7). The highest population minor allele frequency for this variant in gnomAD v3 is 0.05079% (21/41346 alleles) in the African/African American population, which is higher than the ClinGen Myeloid Malignancy VCEP threshold of 0.015% (BS1). The variant also has not been reported in cases or the literature. In summary, this variant meets the criteria to be classified as likely benign for hereditary thrombocytopenia and hematologic cancer predisposition syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy VCEP: BS1, BP4, and BP7 LINK:https://erepo.genome.network/evrepo/ui/classification/CA10014386/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 synonymous
Scores
Clinical Significance
Conservation
Publications
- hereditary thrombocytopenia and hematologic cancer predisposition syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae)
- acute myeloid leukemiaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000204 AC: 31AN: 151992Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.000128 AC: 32AN: 250602 AF XY: 0.000133 show subpopulations
GnomAD4 exome AF: 0.000103 AC: 151AN: 1460416Hom.: 0 Cov.: 33 AF XY: 0.0000991 AC XY: 72AN XY: 726528 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000204 AC: 31AN: 152110Hom.: 0 Cov.: 31 AF XY: 0.000202 AC XY: 15AN XY: 74360 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:2
- -
RUNX1: BP4, BP7 -
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Benign:2
- -
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Inborn genetic diseases Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Benign:1
The c.648C>T (p.Pro216=) variant is a synonymous (silent) variant that is not predicted by SpliceAI to impact splicing (BP4); in addition, an evolutionary conservation algorithm predicts the site as being non-conserved (PhyloP score = -2.75191 in GRCh38), and the variant allele is the reference nucleotide in one primate and/or three mammal species (BP7). The highest population minor allele frequency for this variant in gnomAD v3 is 0.05079% (21/41346 alleles) in the African/African American population, which is higher than the ClinGen Myeloid Malignancy VCEP threshold of 0.015% (BS1). The variant also has not been reported in cases or the literature. In summary, this variant meets the criteria to be classified as likely benign for hereditary thrombocytopenia and hematologic cancer predisposition syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy VCEP: BS1, BP4, and BP7 -
Hereditary cancer-predisposing syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at